|
Innovative Program Doubles Patient Engagement, Cuts Heart Failure …
Virtual-Strategy Magazine (press release) SEATTLE, Dec. 11, 2013 /PRNewswire/ — A San Diego medical group’s disease management program increased patient engagement rates from 28% to 67%, leading to a decline in both hospitalizations and 30-day readmissions for program participants. |
Treasure Coast Christmas Events, updated Dec. 11 – TCPalm
|
Treasure Coast Christmas Events, updated Dec. 11
TCPalm Holidays at McKee: Vintage Wurlitzer band organ playing classic holiday music, model trains, holiday letter writing, visits with Santa, Mrs. Claus’ Serendipity Candy Shop, lights, decorations. 6-8 p.m. Dec. 21-23. … Bring unwrapped toy or monetary … |
Idelalisib plus rituximab extended survival in previously treated CLL – Healio
|
Idelalisib plus rituximab extended survival in previously treated CLL
Healio NEW ORLEANS — The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results presented at the ASH Annual Meeting and Exposition. Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gileads Pipeline EncouragesZacks.com |
Innovative Program Doubles Patient Engagement, Cuts Heart Failure … – PR Newswire (press release)
|
Innovative Program Doubles Patient Engagement, Cuts Heart Failure …
PR Newswire (press release) SEATTLE, Dec. 11, 2013 /PRNewswire/ — A San Diego medical group’s disease management program increased patient engagement rates from 28% to 67%, leading to a decline in both hospitalizations and 30-day readmissions for program participants. |
Could Deceased Heart Attack Victims Expand Donor Pool? – YottaFire
|
Could Deceased Heart Attack Victims Expand Donor Pool?
YottaFire “A primary concern in using organs from donors who suffered a heart attack is the extra donor warm ischemia time—how long it takes to retrieve an organ from donors with non-beating hearts until blood supply ceases to circulate through the tissues … |
Veloxis Pharmaceuticals Announces Initiation of ASERTAA Study of ENVARSUS … – GlobeNewswire (press release)
|
Veloxis Pharmaceuticals Announces Initiation of ASERTAA Study of ENVARSUS …
GlobeNewswire (press release) Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of ENVARSUS® (formerly LCP Tacro™) in kidney transplant recipients. |
Veloxis Pharmaceuticals Announces Initiation of ASERTAA Study of ENVARSUS … – Wall Street Journal
Veloxis Pharmaceuticals Announces Initiation of ASERTAA Study of ENVARSUS …Wall Street JournalThe ASERTAA study is designed to compare the pharmacokinetics (PK) of ENVARSUS(R), a once-daily tacrolimus tablet, to generic twice daily tacrolimus capsule…
Early life exposure to diesel exhaust linked to heart failure in mice. – Environmental Health News
Environmental Health NewsEarly life exposure to diesel exhaust linked to heart failure in mice.Environmental Health NewsWeldy CS, Y Liu, YC Chang, IO Medvedev, JR Fox, TV Larson, WM Chien, MT Chin. In utero and early life exposure to diesel exhaust air…
Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry … – DigitalJournal.com
|
Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry …
DigitalJournal.com Clinical trial report, “Kidney Transplantation Global Clinical Trials Review, H2, 2013″ provides data on the Kidney Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Kidney … |
Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry … – PR Web (press release)
|
Global Kidney Transplantation Clinical Trials Review 2013: Worldwide Industry …
PR Web (press release) Clinical trial report, “Kidney Transplantation Global Clinical Trials Review, H2, 2013″ provides data on the Kidney Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Kidney … |